Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/22/2003US20030096787 Comprising the ITR sequences, a sequence permitting the encapsulation, a heterologous DNA sequence, and in which the E1 gene and at least one of the E2, E4 and L1-L5 genes is non-functional
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096771 8-50 nucleobases targeted to a nucleic acid molecule encoding hormone-sensitive lipase to hybridize with and inhibit expression
05/22/2003US20030096769 Genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096755 Suppression of inhibitors
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096387 Contacting the isomerase with a compound having the structure: A-X-A, where A is radical which mimics the steric and electronic properties of phosphoserin and/or phosphothreonine residue, X= spacer, R is cyclic, heterocylic or aryl ring
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096338 Protein conjugate for use in the treatment of blood disorder
05/22/2003US20030096327 Detection of tumor disorder in humans; obtain tissue sample, screen for presence of tumor marker, presence of marker indicates tumor disorder
05/22/2003US20030096325 Evaluating human sensitivity to antitumor agents; obtain blood sample, monitor blood glutathione concentration, amplified concentration indicates sensitivity to antitumor agents
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096247 Human cDNAs and proteins and uses thereof
05/22/2003US20030096241 Method of testing squamous epithelial cells
05/22/2003US20030096226 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
05/22/2003US20030096225 Recovering preferential protein from library; obtain cell, transform with vector, express vector, isolate preferential protein
05/22/2003US20030096027 Alpha acid, (e.g., humulone) or beta acid (e.g., lupulone)
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003US20030095972 Administration of phosphorylated Mammastatin having a molecular weight of 53 kDa or 49 kDa; the polypeptide is specifically reactive with monoclonal antibody 7G6 that is produced from hybridoma ATCC No. HB10152
05/22/2003US20030095964 Process for producing humanized chimera antibody
05/22/2003US20030095963 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
05/22/2003US20030095960 Three human transferases, polynucleotides that identify and encode them, expression vectors, host cells, antibodies, agonists, and antagonists.
05/22/2003US20030095955 Provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
05/22/2003US20030095953 Methods of reversing drug resistance in cancer cells
05/22/2003US20030095947 Compositions and methods for elimination of unwanted cells
05/22/2003US20030095926 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
05/22/2003US20030095923 System for imaging malignant tumors using carbon 13 with MRI
05/22/2003CA2472019A1 Production of cell suspensions
05/22/2003CA2467391A1 Oligopeptides and compositions containing them as cathepsin s inhibitors
05/22/2003CA2467229A1 Dexrazoxane for treating antitumor-induced cardiotoxicity
05/22/2003CA2467068A1 C-5 modified indazolylpyrrolotriazines
05/22/2003CA2467061A1 Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient
05/22/2003CA2466998A1 Biocompatible polymer blends and uses thereof
05/22/2003CA2466659A1 Anticancer agents
05/22/2003CA2466592A1 Modified anti-tnf alpha antibody
05/22/2003CA2466508A1 Method and pharmaceutical preparations for reducing the activity of cells
05/22/2003CA2466440A1 Cannabinoid receptor ligands
05/22/2003CA2466355A1 Neurotransmitter balance chemotherapy
05/22/2003CA2466115A1 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003CA2466055A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003CA2465893A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003CA2464419A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003CA2460959A1 Enzymes
05/21/2003EP1312609A1 Boronic ester and acid compounds, synthesis and uses
05/21/2003EP1312608A2 Discodermolide analogues and their pharmaceutical use
05/21/2003EP1312601A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
05/21/2003EP1312375A1 Composition having anticancer activity
05/21/2003EP1312367A1 Heterocyclo-alkylsulfonyl pyrazolesa and their use as COX-2 inhibitors
05/21/2003EP1312363A1 Methods of treatment and kits comprising a growth hormone secretagogue
05/21/2003EP1312356A1 Aqueous suspension preparations
05/21/2003EP1311684A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
05/21/2003EP1311678A2 Cripto tumour polypeptide
05/21/2003EP1311677A2 Regulation of human p2y1-like g protein-coupled receptor
05/21/2003EP1311674A2 Compositions and methods for the diagnosis and treatment of tumor
05/21/2003EP1311673A2 Compositions and methods for the therapy and diagnosis of prostate cancer
05/21/2003EP1311672A1 New sequences
05/21/2003EP1311666A2 Progression suppressed gene 13 (psgen 13) and uses thereof
05/21/2003EP1311664A2 Microtubule-associated proteins and tubulins
05/21/2003EP1311663A2 Claudin polypeptides
05/21/2003EP1311660A1 METHOD OF SCREENING FOR INHIBITORS OF HUMAN FATTY ACID-CoA LIGASE 4
05/21/2003EP1311550A2 Synthesis of complex carbohydrates
05/21/2003EP1311539A2 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
05/21/2003EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds
05/21/2003EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311524A2 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
05/21/2003EP1311522A1 New immunoeffector compounds
05/21/2003EP1311519A1 Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same
05/21/2003EP1311514A1 Compositions with vascular damaging activity
05/21/2003EP1311511A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity
05/21/2003EP1311507A1 Fused pyrazole derivatives being protein kinase inhibitors
05/21/2003EP1311500A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity
05/21/2003EP1311489A1 Biphenyl derivatives and the use thereof as integrin inhibitors
05/21/2003EP1311488A1 Substituted imidazoles as tafia inhibitors
05/21/2003EP1311484A1 Biphenyl derivatives and the use thereof as integrin inhibitors
05/21/2003EP1311476A1 Aza-amino acid derivatives (factor x a?-inhibitors 15)
05/21/2003EP1311475A1 Novel aminocyclohexane derivatives
05/21/2003EP1311473A2 Novel compounds inhibiting factor xa activity
05/21/2003EP1311302A2 Pharmaceuticals for the imaging of angiogenic disorders
05/21/2003EP1311298A2 System for regulating in vivo the expression of a transgene by conditional inhibition
05/21/2003EP1311292A2 Vitronectin receptor antagonist pharmaceuticals
05/21/2003EP1311290A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
05/21/2003EP1311288A1 Immunostimulatory nucleic acids for inducing a th2 immune response
05/21/2003EP1311287A2 Transglutaminase for inhibiting angiogenesis
05/21/2003EP1311285A2 Liquid pharmaceutical composition containing an erythropoietin derivative
05/21/2003EP1311267A1 A retroviral immunotherapy
05/21/2003EP1311263A2 Fused pyrrolocarbazoles against inflammation
05/21/2003EP1311262A1 Cancer treatment by combination therapy
05/21/2003EP1311261A1 Medicaments for chemotherapeutic treatment of disease
05/21/2003EP1311259A2 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
05/21/2003EP1311255A1 Compounds having mif antagonist activity
05/21/2003EP1311241A2 Use of a porous carrier
05/21/2003EP1311239A1 Oral delivery of peptide
05/21/2003EP1311213A1 Vaginal delivery of bisphosphonates
1 ... 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 ... 2211